Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- EmergingMarketsllc.com: Emerging Equity Alerts.
- M2 PRESSWIRE-16 June 2006-Emerging Markets Consulting, LLC.: EmergingMarketsllc.com: Emerging Equity AlertsC1994-2006 M2 COMMUNICATIONS LTD RDATE:16062006 Orlando, FL - Stocks gaining traction in yesterday's trading are Millennium Pharmaceuticals, Inc., (NASDAQ: MLNM), Encysive Pharmaceuticals, Inc., (NASDAQ: ENCY), Discovery Laboratories, Inc., (NASDAQ:...
- Research articles 2006-06-16
- "Stocks on the Rise".
- M2 PRESSWIRE-15 June 2005-WallStreetGrapevine: "Stocks on the Rise"C1994-2005 M2 COMMUNICATIONS LTD RDATE:15062005 Wall Street, NYC - Today, wallstreetgrapevine.com, named; FacePrint Global Solutions, Inc. (OTC BB: FCPG), Aastrom Biosciences, Inc. (Nasdaq SC: ASTM), Millennium Pharmaceuticals, Inc. (Nasdaq NM: MLNM), and Abgenix...
- Research articles 2005-06-15
- Zacks.com Announces That Nadine Wong Highlights the Following Stock: Millenium Pharmaceuticals
- CHICAGO -- Nadine Wong is raising sales and earnings estimates for one cancer company, and explains why she expects 2005 to turn to profitability with upside from a massive pipeline. Read about Millenium Pharmaceuticals (NASDAQ:MLNM). Nadine Wong is editor of the Biotech Stock Report newsletter. Click here for the full...
- Research articles 2004-09-28
- Millennium acquires rights to proteasome inhibitors and related synthesis techonology - agreement to augment company's proteasome inhibitor program-.(Millennium Pharmaceuticals Inc.)
- Millennium Pharmaceuticals, Inc. (Cambridge, MA) today announced it has signed a research agreement with Harvard University and Professor E.J. Corey for a family of proteasome inhibitors and a related chemical synthesis process. Millennium intends to utilize the agreement to enhance the Company's ongoing efforts to develop...
- Research articles 2004-05-01
- Cambridge, Mass.-Based Pharmaceutical Firm Expects Big Sales for Cancer Drug.
- By Ross Kerber, The Boston Globe Knight Ridder/Tribune Business News Jan. 13--Millennium Pharmaceuticals Inc. yesterday said it expects to sell up to $160 million worth of its Velcade cancer drug this year, nearly three times its 2003 sales, and said layoffs and...
- Research articles 2004-01-13
- The International Myeloma Foundation Says Newly Diagnosed Patients Could Benefit from FDA "Priority Review" of VELCADE® for Front-Line Use
- NORTH HOLLYWOOD, Calif. -- The International Myeloma Foundation IMF - supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians - today said the FDA decision granting "priority review" for VELCADE[R] in newly diagnosed myeloma recognizes the benefits of powerful new therapies and the need...
- Research articles 2008-02-04
- FDA Approves Millenium's VELCADE -bortezomib- for Use in Second-Line Multiple Myeloma; International Myeloma Foundation Applauds Approval of New Therapy
- NORTH HOLLYWOOD, Calif. -- The International Myeloma Foundation IMF, the country's oldest and largest myeloma organization, applauds the U.S. Food and Drug Administration's FDA approval of VELCADER. This approval expands the label to include the treatment of multiple myeloma patients who have received at least one prior therapy. The approval...
- Research articles 2005-03-29
- Gemin X's Pan-Bcl-2 Antagonist GX15-070 Permits Rational Combination with Velcade in Mantle Cell Lymphoma
- Data Presented in an Oral Presentation at American Society of Hematology Annual Meeting
- Research articles 2006-12-13
- Millennium overhauls operations. (Markets: Life Sciences).(Millennium Pharmaceuticals Inc)
- MILLENNIUM Pharmaceuticals Inc. will trim its global work force by 26 percent and consolidate operations under a restructuring plan for profitability by 2006. The move comes on the heels of a critical Food and Drug Administration FDA approval for MILLENNIUM Pharmaceuticals Inc. will trim...
- Research articles 2003-06-16
- Millennium Announces Promising Early Study Results With VELCADE (Bortezomib) for Injection Combined With Doxil in Patients With Advanced Multiple Myeloma
- In this article Millennium Pharmaceuticals, Inc. discusses the preliminary phase I study results, examining the use of its novel oncology product, VELCADE, in combination with DOXILR doxorubicin liposome injection for the treatment of patients with advanced stage multiple myeloma that have failed multiple prior treatments. Also presented was a combination...
- White papers
- Millennium Announces Preliminary Phase I and Phase II Findings of VELCADE (Bortezomib) for Injection in Studies of Non-Hodgkin's Lymphoma and Solid Tumors
- In this article Millennium Pharmaceuticals, Inc. discusses the results of several clinical trials with its novel oncology product VELCADE, in which early signs of anti-tumor activity were observed with VELCADE as both a single agent and in combination with other therapies. VELCADE Studied as a Single Agent in Non-Hodgkin's Lymphoma...
- White papers 2003-06-02
- FDA Approves VELCADE (Bortezomib) for Injection for the Treatment of Relapsed and Refractory Multiple Myeloma
- This article discusses the Millennium Pharmaceuticals, Inc. approval from the U.S. Food and Drug Administration FDA to market VELCADE for the treatment of multiple myeloma patients who have received at least two prior therapies and have demonstrated disease progression on the last therapy. The effectiveness of VELCADE is based on...
- White papers
- Millennium Initiates Phase II Clinical Trial With Velcade (Bortezomib) for Injection fn Patients With Advanced Non-Small Cell Lung Cancer
- In this article Millennium Pharmaceuticals, Inc. discusses the initiation of a phase II clinical trial of VELCADE in patients with stage IIIb locally advanced or stage IV metastatic non-small cell lung cancer NSCLC. The randomized, open-label study will assess response rates of patients with previously treated NSCLC to treatment with...
- White papers
- Millennium Initiates Phase II Clinical Trial With VELCADE (Bortezomib) for Injection in Patients With Colorectal Cancer
- In this article Millennium Pharmaceuticals, Inc. discusses the recent initiation of a phase II clinical trial of VELCADE in patients with colorectal cancer. The randomized, open-label study assesses the response rates of patients with refractory metastatic colorectal cancer to treatment with VELCADE alone or VELCADE plus CamptosarR irinotecan hydrochloride injection....
- White papers
- Millennium Plans to Submit a New Drug Application for Velcade (Bortezomib) for Injection
- In this article Millennium Pharmaceuticals, Inc. informs that the Company intends to file a New Drug Application NDA with the U.S. Food and Drug Administration FDA to market VELCADE as a treatment for relapsed and refractory multiple myeloma by early 2003. Earlier this year, VELCADE was granted fast-track status by...
- White papers
- Millennium Initiates Pivotal Phase III Clinical Trial Comparing VELCADE (Bortezomib) for Injection With High-Dose Dexamethasone in Patients With Multiple Myeloma
- In this article Millennium Pharmaceuticals, Inc. discusses the initiation of a pivotal phase III clinical trial of VELCADE (formerly known as MLN341, LDP-341 and PS-341) in patients with multiple myeloma, the second most common hematologic cancer. The company also announced they have filed the trade name VELCADE, for trademark registration,...
- White papers 2002-06-11
- Takeda's Spree Peaks With Millennium Buy
- The Japanese are coming! Well, to be exact, one Japanese drugmaker, Takeda Pharmaceutical, is coming. And the big question is whether its recent buying spree -- capped by its $8.8 billion acquisition of the biotech Millennium Pharmaceuticals announced today -- will leave it looking more like...
- Blog posts 2008-04-11
- FDA: Takeda Ad for Velcade Was Not Funny Enough
- The FDA has warned Takeda's Millenium Pharma unit that utilizing a double entendre in a reminder ad is a violation of drug marketing law. The warning letter will be carefully noted by drug marketers their copywriting agencies and compliance departments as another restriction on their creativity. by Jim Edwards
- Blog posts 2009-06-24
- Millennium Initiates Phase II Clinical Trial With VELCADE (Bortezomib) for Injection in Patients With Relapsed or Refractory Mantle Cell Lymphoma
- In this article Millennium Pharmaceuticals, Inc. discusses the initiation of a multicenter phase II clinical trial of VELCADE in patients with relapsed or refractory mantle cell lymphoma. The single-arm, open-label, three-stage study will assess time to progression, response rate, duration of response and overall survival in patients with relapsed or...
- White papers
- Preliminary Phase II Results With VELCADE (Bortezomib) for Injection Demonstrated Activity in Patients With Previously Untreated Multiple Myeloma
- In this article Millennium Pharmaceuticals, Inc. discusses the encouraging preliminary phase II study results from an investigator-initiated study IIS examining the use of VELCADE for the treatment of patients with previously untreated multiple myeloma. The ongoing study being conducted by Dr. Jagannath, M.D., Brian Durie, M.D., of Salick Health Care,...
- White papers
- << Previous
- page 1 of 2
- Next >>
Refining Tags
Premier Vendor Content Whitepapers, webcasts & resources from our Power Center Sponsors
